Skip to main content
. 2015 Nov 17;3:48. doi: 10.1186/s40425-015-0093-x

Table 2.

Most commonly used adjuvants in therapeutic cancer trials

Number of studies including most commonly used adjuvants/immunostimulants
Adjuvant Phase 2 Phase 2/3 Phase 3 Total
GM-CSF 92 1 16 109
Montanide 60 1 5 66
IL-2 53 3 56
KLH 16 8 24
TRICOM 10 3 13
QS21 5 1 6
Poly-ICLC 8 0 0 8